← FDA Drug Approvals (Drugs@FDA)
NINTEDANIB ESYLATE
ANDA · Abbreviated New Drug Application (Generic) · Sponsor: CIPLA · Approved 2026-04-02
Drug application
- FDA Application #
ANDA212609- Application type
- Abbreviated New Drug Application (Generic)
- Brand name
- NINTEDANIB ESYLATE
- Generic name
- NINTEDANIB
- Active ingredients
- NINTEDANIB ESYLATE
- Dosage form
- CAPSULE
- Route
- ORAL
- Marketing status
- Prescription
- Sponsor
- CIPLA
- Manufacturer
- EXELAN PHARMACEUTICALS INC.
- First approval
- 2026-04-02
Source
- Authoritative
- Drugs@FDA application overview
- Machine
- JSON-LD · Markdown